Evidence map›Paper›PMID 26733616›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016

HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.

Andrea Napolitano, Daniel J Antoine, Laura Pellegrini, Francine Baumann, Ian Pagano, Sandra Pastorino, Chandra M Goparaju, Kirill Prokrym, Claudia Canino, Harvey I Pass and 2 more

RetractedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 67 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 5 pooled it
16.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 5 syntheses or guidelines pooled it, 117 citations in OpenAlex.

  1. Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2021
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Review
  7. Review
  8. Review
  9. Pleural mesothelioma.Nature reviews. Disease primers · 2025
    Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Andrea NapolitanoUniversity of Hawaii Cancer Center, Honolulu, Hawaii. Department of Molecular Biosciences and Bioengineering, University of Hawaii at Mānoa, Honolulu, Hawaii.
Daniel J AntoineMRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, United Kingdom.
Laura PellegriniUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Francine BaumannUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Ian PaganoUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Sandra PastorinoUniversity of Hawaii Cancer Center, Honolulu, Hawaii.
Chandra M GoparajuDepartment of Cardiothoracic Surgery, New York University, NYU Langone Medical Center, New York, New York.
Kirill ProkrymDepartment of Cardiothoracic Surgery, New York University, NYU Langone Medical Center, New York, New York.
Claudia CaninoDepartment of Cardiothoracic Surgery, New York University, NYU Langone Medical Center, New York, New York.
Harvey I PassDepartment of Cardiothoracic Surgery, New York University, NYU Langone Medical Center, New York, New York. hyang@cc.hawaii.edu mcarbone@cc.hawaii.edu Harvey.Pass@nyumc.org.
Michele CarboneUniversity of Hawaii Cancer Center, Honolulu, Hawaii. hyang@cc.hawaii.edu mcarbone@cc.hawaii.edu Harvey.Pass@nyumc.org.
Haining YangUniversity of Hawaii Cancer Center, Honolulu, Hawaii. hyang@cc.hawaii.edu mcarbone@cc.hawaii.edu Harvey.Pass@nyumc.org.
Cancer Center of Hawaii · USNYU Langone Health · USUniversity of Hawaiʻi at Mānoa · USUniversity of Liverpool · GB

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI Xin Chen · 1996 to 2026
$56.2M
RESEARCH DESIGN AND BIOSTATISTICS COREU54MD007584 · NIMHD · UNIVERSITY OF HAWAII AT MANOA · PI HEDGES, JERRIS ROBERT, MOKUAU, NOREEN · 2012 to 2018
$21.1M
The North American Mesothelioma ConsortiumU01CA111295 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HUFLEJT, MARGARET ELISABETH, PASS, HARVEY IRA · 2005 to 2016
$4.8M
Germline BAP1 Mutations and Malignant Mesothelioma: Mechanisms and Early DetectionR01CA198138 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI CARBONE, MICHELE · 2015 to 2019
$1.7M
The Role of HMGB1 in the Pathogenesis of MesotheliomaR01CA160715 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI YANG, HAINING · 2011 to 2015
$1.5M
Medical Research Council G0700654Medical Research Council MR/L006758/1NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA160715NCI NIH HHS R01 CA198138NCI NIH HHS U01 CA111295NIMHD NIH HHS U54 MD007584Wellcome Trust
6 · The paper itself

Abstract

purposeTo determine whether serum levels of high mobility group box protein 1 (HMGB1) could differentiate malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls. EXPERIMENTAL

designHyperacetylated and nonacetylated HMGB1 (together referred to as total HMGB1) were blindly measured in blood collected from malignant mesothelioma patients (n = 22), individuals with verified chronic asbestos exposure (n = 20), patients with benign pleural effusions (n = 13) or malignant pleural effusions not due to malignant mesothelioma (n = 25), and healthy controls (n = 20). Blood levels of previously proposed malignant mesothelioma biomarkers fibulin-3, mesothelin, and osteopontin were also measured in nonhealthy individuals.

resultsHMGB1 serum levels reliably distinguished malignant mesothelioma patients, asbestos-exposed individuals, and unexposed controls. Total HMGB1 was significantly higher in malignant mesothelioma patients and asbestos-exposed individuals compared with healthy controls. Hyperacetylated HMGB1 was significantly higher in malignant mesothelioma patients compared with asbestos-exposed individuals and healthy controls, and did not vary with tumor stage. At the cut-off value of 2.00 ng/mL, the sensitivity and specificity of serum hyperacetylated HMGB1 in differentiating malignant mesothelioma patients from asbestos-exposed individuals and healthy controls was 100%, outperforming other previously proposed biomarkers. Combining HMGB1 and fibulin-3 provided increased sensitivity and specificity in differentiating malignant mesothelioma patients from patients with cytologically benign or malignant non-mesothelioma pleural effusion.

conclusionsOur results are significant and clinically relevant as they provide the first biomarker of asbestos exposure and indicate that hyperacetylated HMGB1 is an accurate biomarker to differentiate malignant mesothelioma patients from individuals occupationally exposed to asbestos and unexposed controls. A trial to independently validate these findings will start soon. Clin Cancer Res; 22(12); 3087-96. ©2016 AACR.

Indexed as

Environmental ExposureAcetylationAdultAgedAsbestosBiomarkersExtracellular Matrix ProteinsFemaleGPI-Linked ProteinsHMGB1 ProteinHumansLung NeoplasmsMaleMesothelinMesotheliomaMesothelioma, MalignantAsbestosBiomarkersEFEMP1 protein, humanExtracellular Matrix ProteinsGPI-Linked ProteinsHMGB1 ProteinHMGB1 protein, humanMesothelinOsteopontinSPP1 protein, human

Identifiers

PMID26733616
PMCPMC4867109
OpenAlexW2230894635

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.